Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo

Clin Transl Oncol. 2014 Aug;16(8):753-60. doi: 10.1007/s12094-013-1145-7. Epub 2013 Dec 12.

Abstract

Background: Immunotherapy is an effective method for preventing metastasis and recurrence of carcinoma. Hepatocellular carcinoma (HCC) is a common malignancy with a high rate of recurrence, and has not successfully been introduced to immunotherapy.

Methods: Peripheral blood mononuclear cells were isolated from whole blood of HCC patients and stimulated to transform into dendritic cells (DCs). These DCs were then transfected with RNA extracted from HepG-2 hepatoma cells to induce expression of specific antigens.

Results: The transfected DCs stimulated T lymphocytes to produce cytotoxic T lymphocytes, which specifically attacked HepG-2 cells. Injection of T lymphocytes from HCC patients and transfected DCs into severe combined immunodeficiency mice limited the growth of HepG-2 tumors.

Conclusion: A specific immune response against hepatoma can be generated in vivo by administering DCs transfected with RNA from a specific tumor. This method may have therapeutic application in humans to reduce recurrence of HCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Cancer Vaccines / immunology*
  • Carcinoma, Hepatocellular / immunology*
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation*
  • Flow Cytometry
  • Humans
  • In Vitro Techniques
  • Liver Neoplasms / immunology*
  • Mice
  • RNA, Neoplasm / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Transfection
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • RNA, Neoplasm